申请人:Merck Sharp & Dohme Ltd.
公开号:US06723735B1
公开(公告)日:2004-04-20
The present invention is directed to 3-phenylimidazol[4,5-b]pyridine derivatives, that are selective ligands for GABAA receptors. These compounds are useful in the treatment and prevention of disorders of the central nervous system, including anxiety and convulsions.
本发明涉及选择性GABAA受体配体的3-苯基咪唑并[4,5-b]吡啶衍生物。这些化合物可用于治疗和预防中枢神经系统疾病,包括焦虑和抽搐。